Trump Team Testing ‘Off-the-Shelf’ Drugs to Cure Coronavirus
(Bloomberg) -- The Trump administration is testing existing “off-the-shelf” drugs to combat the coronavirus, a cabinet official said Saturday.
A national lab in Tennessee recently made “an important discovery” involving existing drugs, Energy Secretary Dan Brouillette said at the Conservative Political Action Conference in Maryland.
“The scientists at our Oak Ridge National Laboratory were able to look at the protein strains and determine -- perhaps, it's still early -- that we can find some off-the-shelf drugs that can help us not only cure the disease but stop the spread of the infection,” Brouillette said.
Brouillette was responding to a question about what his agency is doing to help combat the virus, which has caused markets to plunge and killed nearly 3,000 people across the globe. In the U.S., where 22 cases have been reported, the virus has killed one person -- a woman from Washington state -- and more cases are likely, President Donald Trump said Saturday.
In addition to the laboratory tests, Brouillette said he's harnessing the power of his agency's “super computers” as well as artificial intelligence capabilities to assist organizations like the Centers for Disease Control and the World Heath Organization to conduct modeling on the virus.
“We want to know how far is this going to spread and at what point might it peak,” he said.
To contact the reporter on this story: Ari Natter in Washington at anatter5@bloomberg.net
To contact the editors responsible for this story: Jon Morgan at jmorgan97@bloomberg.net, Matthew G. Miller, Virginia Van Natta
©2020 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.